These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 29983309

  • 61. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
    de Oliveira CC, Brizeno LA, de Sousa FB, Mota MR, Alves AP.
    Med Oral Patol Oral Cir Bucal; 2016 Jul 01; 21(4):e431-9. PubMed ID: 26827069
    [Abstract] [Full Text] [Related]

  • 62. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M, Kuroshima S, Sawase T.
    Int J Implant Dent; 2021 May 14; 7(1):47. PubMed ID: 33987769
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].
    Tröltzsch M, Tröltzsch M, Pautke C, Otto S.
    HNO; 2022 Jul 14; 70(7):499-507. PubMed ID: 35050392
    [Abstract] [Full Text] [Related]

  • 66. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
    Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.
    Ann Oncol; 2012 May 14; 23(5):1341-1347. PubMed ID: 21986094
    [Abstract] [Full Text] [Related]

  • 67. Ultrasonic Piezoelectric Bone Surgery Combined With Leukocyte and Platelet-Rich Fibrin and Pedicled Buccal Fat Pad Flap in Denosumab-Related Osteonecrosis of the Jaw.
    Şahin O, Odabaşi O, Ekmekcioğlu C.
    J Craniofac Surg; 2019 Jul 14; 30(5):e434-e436. PubMed ID: 31299805
    [Abstract] [Full Text] [Related]

  • 68. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
    Takaoka K, Kishimoto H.
    Nihon Yakurigaku Zasshi; 2019 Jul 14; 153(1):22-27. PubMed ID: 30643088
    [Abstract] [Full Text] [Related]

  • 69. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E, Bamias A.
    Eur J Cancer Care (Engl); 2017 Nov 14; 26(6):. PubMed ID: 29063702
    [Abstract] [Full Text] [Related]

  • 70. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
    Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, Helm A, Bornstein MM, Molinero-Mourelle P.
    Med Oral Patol Oral Cir Bucal; 2020 May 01; 25(3):e326-e336. PubMed ID: 32271321
    [Abstract] [Full Text] [Related]

  • 71. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
    Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W.
    Sci Rep; 2022 May 23; 12(1):8641. PubMed ID: 35606457
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Medication-related osteonecrosis of the jaw: A literature review.
    Kuroshima S, Sasaki M, Sawase T.
    J Oral Biosci; 2019 Jun 23; 61(2):99-104. PubMed ID: 31109863
    [Abstract] [Full Text] [Related]

  • 74. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
    Wei LY, Kok SH, Lee YC, Chiu WY, Wang JJ, Cheng SJ, Chang HH, Lee JJ.
    Oral Dis; 2022 Jan 23; 28(1):182-192. PubMed ID: 33254278
    [Abstract] [Full Text] [Related]

  • 75. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T.
    Support Care Cancer; 2022 Mar 23; 30(3):2341-2348. PubMed ID: 34738163
    [Abstract] [Full Text] [Related]

  • 76. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V, Campisi G, Bedogni A.
    Support Care Cancer; 2022 Sep 23; 30(9):7047-7051. PubMed ID: 35312858
    [Abstract] [Full Text] [Related]

  • 77. Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw.
    Yasui T, Kimura M, Nagamine H, Yajima S, Karube T, Sato H, Asoda S, Hara S, Onizawa K.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Mar 23; 131(3):312-318. PubMed ID: 33431343
    [Abstract] [Full Text] [Related]

  • 78. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
    Zhang C, Shen G, Li H, Xin Y, Shi M, Zheng Y, Wang M, Liu Z, Zhao Y, Zhao F, Ren D, Zhao J.
    Spec Care Dentist; 2024 Mar 23; 44(2):530-541. PubMed ID: 37219080
    [Abstract] [Full Text] [Related]

  • 79. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
    Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, Farooki A, Fornier M, Huryn JM, Estilo CL.
    J Craniomaxillofac Surg; 2016 Mar 23; 44(3):265-70. PubMed ID: 26782845
    [Abstract] [Full Text] [Related]

  • 80. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
    Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M.
    Oral Dis; 2018 Mar 23; 24(1-2):52-56. PubMed ID: 29480637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.